Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation-Induced Hemorrhagic Cystitis: A Systematic Review and Meta-Analysis

Radiation-induced hemorrhagic cystitis (RHC) is a chronic inflammatory disease in patients undergoing radiation therapy that causes a cluster of symptoms which may have a latent period of months to years. The current non-invasive treatments include drug treatment and hyperbaric oxygen therapy (HBOT)...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2024-08, Vol.13 (16), p.4724
Main Authors: Yang, Teng-Kai, Wang, Yu-Jen, Li, Hsing-Ju, Yu, Ya-Fang, Huang, Kai-Wen, Cheng, Jason Chia-Hsien
Format: Article
Language:English
Subjects:
Adjuvants
Bias
Clinical trials
Gynecology
Hematuria
Hyaluronic acid
Meta-analysis
Oxygen therapy
Radiation therapy
Remission (Medicine)
Statistical analysis
Systematic Review
Urination
Urogenital system
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Radiation-induced hemorrhagic cystitis (RHC) is a chronic inflammatory disease in patients undergoing radiation therapy that causes a cluster of symptoms which may have a latent period of months to years. The current non-invasive treatments include drug treatment and hyperbaric oxygen therapy (HBOT), which has been widely applied for RHC so far but with limited evidence. Thus, we conducted a systematic review and meta-analysis to clarify the effects and safety of HBOT for RHC. A systematic review and meta-analysis were utilized, searching in the databases of Embase, Pubmed, and Web of Science. The primary endpoint of the present study was complete remission of hematuria. The meta-analysis was conducted using a random effects model, and a pooled odds ratio with 95% CI was calculated. A total of 317 studies were searched and fourteen articles with 556 patients were collected. The results showed that a total of 500 patients (89.9%) had symptom improvement, and the pooled results demonstrated that 55% of patients with HBOT had complete remission of hematuria (95% CI 51-59%). A significant improvement of symptoms when treated with HBOT was shown in this meta-analysis for patients with RHC.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm13164724